Wuhan YZY Biopharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	66.86	107.81	-	-	-
Other Revenue	-	-	-	2.28	12.16
Revenue	66.86	107.81	-	2.28	12.16
Revenue Growth (YoY)	-37.99%	-	-	-81.28%	-
Cost of Revenue	56.12	22.74	-	-	-
Gross Profit	10.74	85.07	-	2.28	12.16
Selling, General & Admin	22.81	26.59	22.31	20.53	31.5
Research & Development	78.2	164.99	155.05	157.33	112.89
Other Operating Expenses	-10.47	-8.53	-11.97	-	-
Operating Expenses	90.54	183.05	165.4	177.85	144.39
Operating Income	-79.8	-97.98	-165.4	-175.58	-132.23
Interest Expense	-4.95	-4.08	-2.39	-2.47	-14.97
Interest & Investment Income	-	2.57	1.05	0.28	0.16
Currency Exchange Gain (Loss)	-	1.95	-1.92	-	-
Other Non Operating Income (Expenses)	0.02	-	-24.63	-11.77	-2.67
EBT Excluding Unusual Items	-84.73	-97.54	-193.29	-189.53	-149.71
Gain (Loss) on Sale of Investments	-	-	1.61	0.67	1.26
Gain (Loss) on Sale of Assets	-	-0.07	-0.02	-0	-0.55
Other Unusual Items	-	0.01	-	-	0.47
Pretax Income	-84.73	-97.6	-191.7	-188.87	-148.52
Net Income	-84.73	-97.6	-191.7	-188.87	-148.52
Net Income to Common	-84.73	-97.6	-191.7	-188.87	-148.52
Shares Outstanding (Basic)	193	194	185	172	152
Shares Outstanding (Diluted)	193	194	185	172	152
Shares Change (YoY)	-0.66%	4.72%	7.60%	13.10%	-
EPS (Basic)	-0.44	-0.50	-1.04	-1.10	-0.98
EPS (Diluted)	-0.44	-0.50	-1.04	-1.10	-0.98
Free Cash Flow	-	-102.22	-187.95	-178.11	-100.61
Free Cash Flow Per Share	-	-0.53	-1.01	-1.03	-0.66
Gross Margin	16.06%	78.90%	-	100.00%	100.00%
Operating Margin	-119.36%	-90.88%	-	-7710.89%	-1087.03%
Profit Margin	-126.73%	-90.53%	-	-8294.51%	-1220.96%
Free Cash Flow Margin	-	-94.81%	-	-7822.31%	-827.14%
EBITDA	-73.83	-92.01	-158.99	-169.23	-125.2
EBITDA Margin	-110.43%	-85.34%	-	-	-
D&A For EBITDA	5.97	5.97	6.41	6.34	7.03
EBIT	-79.8	-97.98	-165.4	-175.58	-132.23
EBIT Margin	-119.36%	-90.88%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.